Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sarcoma 1Rectal Neoplasms 1Odontogenic Cysts 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Cancer 1Lung Neoplasms 1Liver Neoplasms 1Head and Neck Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1Anus Neoplasms 1

Interventions

lutetium Lu 177 dotatate 5Data Collection 3telotristat ethyl 2Somatostatin 2Positron-Emission Tomography 2Magnetic Resonance Spectroscopy 2Everolimus 2Drug Therapy 2Biopsy 2surufatinib 1lanreotide 1copper dotatate CU-64 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Sorafenib 1Salvage Therapy 1Radionuclide Imaging 1Radiomics 1Radiofrequency Ablation 1Quality of Life 1Plastic Surgery Procedures 1Phlebotomy 1Patient Reported Outcome Measures 1Octreotide 1Molecular Diagnostic Techniques 1Lutetium-177 1Lutetium 1Liver Transplantation 1Laparoscopy 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Neuroendocrine Tumors × Radionuclide Imaging × Clear all
NCT06448208 2026-03-09

Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors

Memorial Sloan Kettering Cancer Center

Active not recruiting
11 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡